KRAS and non-small cell lung carcinoma: Considering that patients with currently approved clinically actionable alterations (i.e., EGFR, ALK, ROS1, RET and BRAF) account for 15–20% of non-squamous NSCLC and rapid emergence of additional targets (e.g., MET alterations, KRAS G12C), a shift towards diagnostic platforms that allow multigene panel testing (e.g., NGS technology) is the most appropriate approach, as opposed to sequential single-gene testing such as FISH or RT-PCR.